Valneva (NASDAQ:VALN) Receives Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Valneva (NASDAQ:VALN) in a report published on Friday morning,Benzinga reports. They currently have a $18.00 price target on the stock.

Valneva Stock Up 10.1 %

Valneva stock opened at $5.78 on Friday. The firm has a 50 day simple moving average of $4.35 and a 200 day simple moving average of $5.70. The company has a current ratio of 2.78, a quick ratio of 2.25 and a debt-to-equity ratio of 0.70. Valneva has a 1-year low of $3.62 and a 1-year high of $9.50.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Valneva stock. ABC Arbitrage SA acquired a new stake in shares of Valneva SE (NASDAQ:VALN) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 19,244 shares of the company’s stock, valued at approximately $84,000. 11.39% of the stock is owned by institutional investors and hedge funds.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.